Scottish Medicines Consortium

zoledronic acid 5mg/100ml solution for infusion (Aclasta®) (No. 535/08)

Novartis Pharmaceuticals UK Ltd

Statement of Advice

05 December 2008

ADVICE: in the absence of a submission from the holder of the marketing authorisation.

zoledronic acid 5mg (Aclasta®) is not recommended for use within NHSScotland for the treatment of osteoporosis in men at increased risk of fracture, including those with a recent low-trauma hip fracture.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chairman,
Scottish Medicines Consortium

Published 12 January 2009

Secretariat - Delta House 50 West Nile Street Glasgow G1 2NP
Telephone 0141 225 6997 Fax 0141 248 3778
E-mail rosie.murray@nhs.net

Chairman Dr Kenneth R Paterson